FULGENT GENETICS, INC. Payment for Contingent Consideration Liability, Investing Activities
FULGENT GENETICS, INC. (FLGT) reported Payment for Contingent Consideration Liability, Investing Activities of $10.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities · last filed 2025-02-28
- FULGENT GENETICS, INC. payment for contingent consideration liability, investing activities for the quarter ending 2022-12-31 was $0.00.
- FULGENT GENETICS, INC. payment for contingent consideration liability, investing activities for the quarter ending 2022-09-30 was $0.00.
- FULGENT GENETICS, INC. payment for contingent consideration liability, investing activities for the quarter ending 2022-06-30 was $0.00.
- FULGENT GENETICS, INC. payment for contingent consideration liability, investing activities for the quarter ending 2022-03-31 was $10.00M.
- FULGENT GENETICS, INC. payment for contingent consideration liability, investing activities for fiscal 2022 was $10.00M.
| Period end | Payment for Contingent Consideration Liability, Investing Activities 3 month | Payment for Contingent Consideration Liability, Investing Activities 6 month | Payment for Contingent Consideration Liability, Investing Activities 9 month | Payment for Contingent Consideration Liability, Investing Activities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $10.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $10.00M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $10.00M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $10.00M 10-Q · filed 2023-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |